The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
NICE news for carfilzomib
In June 2017, Amgen’s drug carfilzomib was approved by the National Institute for Health and Care Excellence (NICE) for the treatment of patients with Multiple Myeloma (MM), in combination with dexamethasone. Carfilzomib is recommended for the treatment of adult MM patients that have relapsed and had one prior treatment that does not include the proteasome inhibitor (PI) bortezomib. Data from the ENDEAVOR clinical trial was pivotal in this decision, which showed it is superior to bortezomib, in combination with dexamethasone, and can significantly extend progression free survival (PFS) with limited adverse events (AEs). Carfilzomib is administered intravenously and binds irreversibly to the 20S proteasome, inhibiting its activity and leading to cell cycle arrest. This will be welcome news for MM patients in the UK with relapsed disease, who are seeking new and effective options.
References